Bedaiwy Mohamed A, Allaire Catherine, Alfaraj Sukinah
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Fertil Steril. 2017 Mar;107(3):537-548. doi: 10.1016/j.fertnstert.2016.12.024. Epub 2017 Jan 27.
Endometriosis can recur after either surgical or medical therapy. Long-term medical therapy is implemented to treat symptoms or prevent recurrence. Dienogest and gonadotropin-releasing hormone (GnRH) analogues with hormone add-back therapy seem to be equally effective for long-term treatment of pain symptoms associated with endometriosis. There is insufficient evidence to support the superiority of one therapy over the other. However, add-back hormone therapy (HT) is recommended for patients using GnRH agonists. The treatment selection depends on therapeutic effectiveness, tolerability, drug cost, the physician's experience, and expected patient compliance.
子宫内膜异位症在手术或药物治疗后均可能复发。实施长期药物治疗以缓解症状或预防复发。地诺孕素和促性腺激素释放激素(GnRH)类似物联合激素补充疗法,对于子宫内膜异位症相关疼痛症状的长期治疗似乎同样有效。尚无充分证据支持一种疗法优于另一种疗法。然而,对于使用GnRH激动剂的患者,建议采用激素补充疗法(HT)。治疗方案的选择取决于治疗效果、耐受性、药物成本、医生经验以及患者预期的依从性。